Abstract
Stroke is the third most common cause of death worldwide following ischemic heart disease and cancer and the number one condition associated with permanent disability. In Western countries, the yearly incidence of stroke is ∼ 0.2% of the population and the number of stroke-related death is expected to double over the next 30 years. Studies from the Netherlands and Scotland showed that stroke accounted for 3% to 5% of their total health care resources. For 2006, the estimated direct and indirect cost of stroke in the United States was ∼ 60 billion. Significant stenosis of the internal carotid artery is responsible for 10% to 20% of all strokes or transient ischemic attacks. Large-scale randomized clinical trials have established the superiority of carotid endarterectomy (CEA) over medical management in patients with high-grade stenosis of the internal carotid artery, particularly among symptomatic patients. Although percutaneous carotid revascularization has been performed since the early eighties, the enthusiasm has long been tempered by the fear of cerebral embolism. Following the introduction of emboli protection devices (EPD) around the year 2000, the number of procedures performed worldwide has grown exponentially. We review the available studies on carotid stenting and discuss appropriate use of this procedure. Emphasis is also placed on optimal long-term pharmacotherapy in patients with carotid stenosis.
Keywords: Carotid stenosis, carotid endarterectomy, carotid stenting, secondary prevention
Current Vascular Pharmacology
Title: Current Status of Carotid Stenting
Volume: 6 Issue: 2
Author(s): Ji Sun Kim and Debabrata Mukherjee
Affiliation:
Keywords: Carotid stenosis, carotid endarterectomy, carotid stenting, secondary prevention
Abstract: Stroke is the third most common cause of death worldwide following ischemic heart disease and cancer and the number one condition associated with permanent disability. In Western countries, the yearly incidence of stroke is ∼ 0.2% of the population and the number of stroke-related death is expected to double over the next 30 years. Studies from the Netherlands and Scotland showed that stroke accounted for 3% to 5% of their total health care resources. For 2006, the estimated direct and indirect cost of stroke in the United States was ∼ 60 billion. Significant stenosis of the internal carotid artery is responsible for 10% to 20% of all strokes or transient ischemic attacks. Large-scale randomized clinical trials have established the superiority of carotid endarterectomy (CEA) over medical management in patients with high-grade stenosis of the internal carotid artery, particularly among symptomatic patients. Although percutaneous carotid revascularization has been performed since the early eighties, the enthusiasm has long been tempered by the fear of cerebral embolism. Following the introduction of emboli protection devices (EPD) around the year 2000, the number of procedures performed worldwide has grown exponentially. We review the available studies on carotid stenting and discuss appropriate use of this procedure. Emphasis is also placed on optimal long-term pharmacotherapy in patients with carotid stenosis.
Export Options
About this article
Cite this article as:
Kim Sun Ji and Mukherjee Debabrata, Current Status of Carotid Stenting, Current Vascular Pharmacology 2008; 6 (2) . https://dx.doi.org/10.2174/157016108783955347
DOI https://dx.doi.org/10.2174/157016108783955347 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Selections
Recent Patents on Cardiovascular Drug Discovery Oxidative/Nitrosative Brain Damage in Stress: Possible Target for Neuropsychopharmacological Drugs
Current Medicinal Chemistry - Central Nervous System Agents Older Adults Prescribed Methadone: A Review of the Literature Across the Life Span from Opiate Initiation to Methadone Maintenance Treatment
Current Drug Abuse Reviews Pregabalin in Neuropathic Pain: Evidences and Possible Mechanisms
Current Neuropharmacology Drug Withdrawal and Hyperphagia: Lessons from Tobacco and Other Drugs
Current Pharmaceutical Design Novel Perspective for Antithrombotic Therapy in TAVI
Current Pharmaceutical Design Side Effects of AAS Abuse: An Overview
Mini-Reviews in Medicinal Chemistry Assessing Systemic Arterial Hypertension Through Echocardiography: A Review for the Clinician
Current Hypertension Reviews The Role of Small, Dense Low-Density-Lipoproteins in Non-Coronary Forms of Atherosclerosis
Vascular Disease Prevention (Discontinued) Cardiac Arrhythmias in Patients with Chronic Kidney Disease: Implications of Renal Failure for Antiarrhythmic Drug Therapy
Current Medicinal Chemistry Hypothyroidism and Nephrotic Syndrome: Why, When and How to Treat
Current Vascular Pharmacology Drugs for the Treatment of Hypercholesterolemia and their Benefits Beyond Cholesterol Lowering to Prevent Vascular Disease
Vascular Disease Prevention (Discontinued) Choosing a Revascularization Strategy in Patients with Diabetes and Stable Coronary Artery Disease: A Complex Decision
Current Cardiology Reviews Bioenergetics and Mitochondrial Dysfunction in Aging: Recent Insights for a Therapeutical Approach
Current Pharmaceutical Design Historical Aspects and Relevance of the Human Coronary Collateral Circulation
Current Cardiology Reviews Dietary Transition in the South Asian Diaspora: Implications for Diabetes Prevention Strategies
Current Diabetes Reviews A New Practice: Study on the Molecular Mechanism of Traditional Chinese Medicine by Computational Pharmacology Methods: Part 2: Pharmacodynamic Modeling and Distribution on Ligand-Target Space of Effective Components
Letters in Drug Design & Discovery C-reactive Protein, Infection, and Outcome After Acute Ischemic Stroke: A Registry and Systematic Review
Current Neurovascular Research Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Recent Patents on Drug Delivery & Formulation An Experimental and Theoretical Approach to Understand Fever, DENF & its Cure
Infectious Disorders - Drug Targets